GOAL: multicenter, open-label, post-marketing study of flavocoxid, a novel dual pathway inhibitor anti-inflammatory agent of botanical origin

References

• Burnett BP, Levy R, Cole BJ. Metabolic mechanisms in the pathogenesis of osteoarthritis. a review. J Knee Surg 2006;19:191-7
   PubMedGoogle Scholar
• Paulus HE. FDA arthritis advisory committee meeting: serious gastrointestinal toxicity of nonsteroidal anti-inflammatory drugs, etc. Arthritis Rheum 1988;31:1450-1
   Web of Science ®Google Scholar
• Garcia Rodriguez LA, Jick H. Risk of upper gastrointestinal bleeding and perforation associated with individual non-steroidal anti-inflammatory drugs. Lancet 1994;343:769-72
   PubMed Web of Science ®Google Scholar
• Cronberg S, Wallmark E, Soderberg I. Effect on platelet aggregation of oral administration of 10 non-steroidal analgesics to humans. Scand J Haematol 1984;33:155-9
   PubMedGoogle Scholar
• Lu HL. Statistical reviewer briefing document for the advisory committee. Celebrex NDA20-998
   Google Scholar
• Grosser T, Fries S, FitzGerald GA. Biological basis for the cardiovascular consequences of COX-2 inhibition: therapeutic challenges and opportunities. J Clin Invest 2006;116:4-15
   PubMed Web of Science ®Google Scholar
• Silverstein FE, Faich G, Goldstein JL, et al. Gastrointestinal toxicity with celecoxib vs. nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. JAMA 2000;284:1247-55
   PubMed Web of Science ®Google Scholar
• Wallace JL. Nonsteroidal anti-inflammatory drugs and gastroenteropathy: the second hundred years. Gastroenterology 1997;112:1000-16
   PubMed Web of Science ®Google Scholar
• Andrews FJ, Malcontenti-Wilson C, O'Brien PE. Effect of nonsteroidal anti-inflammatory drugs on LFA-1 and ICAM-1 expression in gastric mucosa. Am J Physiol 1994;266:G657-64
   PubMed Web of Science ®Google Scholar
• Wallace JL, McKnight W, Reuter BK, et al. NSAID-induced gastric damage in rats: requirement for inhibition of both cyclooxygenase 1 and 2. Gastroenterology 2000;119:706-14
   PubMed Web of Science ®Google Scholar
• Bombardier C, Laine L, Reicin A, et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med 2000;343:1520-8
   PubMed Web of Science ®Google Scholar
• Stockl K, Cyprien L, Chang EY. Gastrointestinal bleeding rates among managed care patients newly started on COX-2 inhibitors or nonselective NSAIDs. J Manag Care Pharm 2005;11:550-8
   PubMedGoogle Scholar
• Juni P, Rutjes AW, Dieppe PA. Are selective COX 2 inhibitors superior to traditional non steroidal anti-inflammatory drugs?. BMJ 2002;324:1287-8
   PubMed Web of Science ®Google Scholar
• Zimmermann KC, Sarbia M, Schror K, et al. Constitutive cyclooxygenase-2 expression in healthy human and rabbit gastric mucosa. Mol Pharmacol 1998;54:536-40
   PubMed Web of Science ®Google Scholar
• Baatar D, Jones MK, Pai R, et al. Selective cyclooxygenase-2 blocker delays healing of esophageal ulcers in rats and inhibits ulceration-triggered c-Met/hepatocyte growth factor receptor induction and extracellular signal-regulated kinase 2 activation. Am J Pathol 2002;160:963-72
   PubMed Web of Science ®Google Scholar
• Martel-Pelletier J. Proinflammatory mediators and osteoarthritis. Osteoarthr Cartil 1999;7:315-16
   PubMed Web of Science ®Google Scholar
• Martel-Pelletier J, Lajeunesse D, Reboul P, et al. Therapeutic role of dual inhibitors of 5-LOX and COX, selective and non-selective non-steroidal anti-inflammatory drugs. Ann Rheum Dis 2003;62:501-9
   PubMed Web of Science ®Google Scholar
• Martel-Pelletier J, Mineau F, Fahmi H, et al. Regulation of the expression of 5-lipoxygenase-activating protein/5-lipoxygenase and the synthesis of leukotriene B(4) in osteoarthritic chondrocytes: role of transforming growth factor beta and eicosanoids. Arthritis Rheum 2004;50:3925-33
   PubMed Web of Science ®Google Scholar
• Hudson N, Balsitis M, Everitt S, et al. Enhanced gastric mucosal leukotriene B4 synthesis in patients taking non-steroidal anti-inflammatory drugs. Gut 1993;34:742-7
   PubMed Web of Science ®Google Scholar
• Singh VP, Patil CS, Kulkarni SK. Effect of licofelone against NSAIDs-induced gastrointestinal ulceration and inflammation. Indian J Exp Biol 2005;43:247-53
   PubMedGoogle Scholar
• Asako H, Kubes P, Wallace JL, et al. Indomethacin induced leukocyte adhesion in mesenteric venules: role of lipoxygenase products. Am J Physiol 1992;262:G903-8
   PubMed Web of Science ®Google Scholar
• Huang JQ, Sridhar S, Hunt RH. Role of Helicobacter pylori infection and non-steroidal anti-inflammatory drugs in peptic-ulcer disease: a meta-analysis. Lancet 2002;359:14-22
   PubMed Web of Science ®Google Scholar
• Burnett BP, Jia Q, Zhao Y, et al. A medicinal extract of Scutellaria baicalensis and Acacia catechu acts as a dual inhibitor of cyclooxygenase and 5-lipoxygenase to reduce inflammation. J Med Food 2007;10:442-51
   PubMed Web of Science ®Google Scholar
• Levy R, Saikovsky R, Shmidt E, et al. Flavocoxid is as effective as naproxen for managing the signs and symptoms of osteoarthritis of the knee in humans: a short-term randomized, double-blind pilot study. Nutr Res 2009;29:298-304
   PubMed Web of Science ®Google Scholar
• Altavilla D, Squadrito F, Bitto A, et al. Flavocoxid, a dual inhibitor of cyclooxygenase and 5-lipoxygenase, blunts pro-inflammatory phenotype activation in endotoxin stimulated macrophages. Br J Pharmacol 2009;157:1410-18
   PubMed Web of Science ®Google Scholar
• Vecka M, Prokes L, Tvrzicka E, et al. Anti-inflammatory activities of flavonoids from Comfort-G and the changes in arachidonic acid metabolism. Klin Biochem Metab 2008;16:27-32
   Google Scholar
• Burnett BP, Silva S, Mesches MH, et al. Safety evaluation of a combination, defined extract of Scutellaria baicalensis and Acacia catechu. J Food Biochem 2007;31:797-825
   Web of Science ®Google Scholar
• Morgan SL, Baggott JE, Moreland L, et al. The safety of flavocoxid, a medical food, in the dietary management of knee osteoarthritis. J Medicinal Foods 2008;12:1-6
   Web of Science ®Google Scholar
• Levy RM, Khokhlov A, Kopenkin S, et al. Efficacy and safety of flavocoxid: a novel therapeutic, compared with naproxen, in subjects with osteoarthritis of the knee. 2010:Submitted
   Google Scholar
• Bent S, Padula A, Avins AL. Brief communication: Better ways to question patients about adverse medical events: a randomized, controlled trial. Ann Intern Med 2006;144:257-61
   PubMed Web of Science ®Google Scholar
• Kaluzny JJ, Szaflik J, Czechowicz-Janicka K, et al. Timolol 0.5%/dorzolamide 2% fixed combination versus timolol 0.5%/pilocarpine 2% fixed combination in primary open-angle glaucoma or ocular hypertensive patients. Acta Ophthalmol Scand 2003;81:349-54
   PubMedGoogle Scholar
• Stewart WC, Day DG, Stewart JA, et al. Short-term ocular tolerability of dorzolamide 2% and brinzolamide 1% vs. placebo in primary open-angle glaucoma and ocular hypertension subjects. Eye (Lond) 2004;18:905-10
   PubMed Web of Science ®Google Scholar
• Day DG, Sharpe ED, Beischel CJ, et al. Safety and efficacy of bimatoprost 0.03% versus timolol maleate 0.5%/dorzolamide 2% fixed combination. Eur J Ophthalmol 2005;15:336-42
   PubMed Web of Science ®Google Scholar
• Jones CW. A post-marketing surveillance study of Voltarol 75 mg SR in the primary care setting. Br J Clin Pract 1996;50:390-5
   PubMedGoogle Scholar
• http://www.emea.europa.eu/humandocs/PDFs/EPAR/onsenal/370303en6.pdf
   Google Scholar
• Moore RA, Derry S, Phillips CJ, et al. Nonsteroidal anti-inflammatory drugs (NSAIDs), cyxlooxygenase-2 selective inhibitors (coxibs) and gastrointestinal harm: review of clinical trials and clinical practice. BMC Musculoskelet Disord 2006;7:79
   PubMed Web of Science ®Google Scholar
• Butt JH, Barthel JS, Hosokawa MC, et al. NSAIDs: a clinical approach to the problems of gastrointestinal side-effects. Aliment Pharmacol Ther 1988;2(Suppl 1):121-9
   PubMed Web of Science ®Google Scholar
• Walker AM, Chan KW, Yood RA. Patterns of interchange in the dispensing of non-steroidal anti-inflammatory drugs. J Clin Epidemiol 1992;45:187-95
   PubMed Web of Science ®Google Scholar
• Langman M, Kahler KH, Kong SX, et al. Drug switching patterns among patients taking non-steroidal anti-inflammatory drugs: a retrospective cohort study of a general practitioners database in the United Kingdom. Pharmacoepidemiol Drug Saf 2001;10:517-24
   PubMed Web of Science ®Google Scholar
• Leufkens HG, Ameling CB, Hekster YA, et al. Utilization patterns of non-steroidal anti-inflammatory drugs in an open Dutch population. Pharm Weekbl Sci 1990;12:97-103
   PubMedGoogle Scholar
• Larkai EN, Smith JL, Lidsky MD, et al. Dyspepsia in NSAID users: the size of the problem. J Clin Gastroenterol 1989;11:158-62
   PubMed Web of Science ®Google Scholar
• Smalley WE, Griffin MR. The risks and costs of upper gastrointestinal disease attributable to NSAIDs. Gastroenterol Clin North Am 1996;25:373-96
   PubMed Web of Science ®Google Scholar
• Fries JF. NSAID gastropathy: the second most deadly rheumatic disease? Epidemiology and risk appraisal. J Rheumatol Suppl 1991;28:6-10
   PubMedGoogle Scholar
• Smalley WE, Griffin MR, Fought RL, et al. Excess costs from gastrointestinal disease associated with nonsteroidal anti-inflammatory drugs. J Gen Intern Med 1996;11:461-9
   PubMed Web of Science ®Google Scholar
• Singh G. Recent considerations in nonsteroidal anti-inflammatory drug gastropathy. Am J Med 1998;105:31-8S
   PubMedGoogle Scholar
• Altman RD. Intra-articular sodium hyaluronate in osteoarthritis of the knee. Semin Arthritis Rheum 2000;30:11-18
   PubMed Web of Science ®Google Scholar
• Arroyo M, Lanas A. NSAIDs-induced gastrointestinal damage. Review. Minerva Gastroenterol Dietol 2006;52:249-59
   PubMedGoogle Scholar
• Hippisley-Cox J, Coupland C. Risk of myocardial infarction in patients taking cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs: population based nested case-control analysis. BMJ 2005;330:1366
   PubMed Web of Science ®Google Scholar
• Kimmey MB, Lanas A. Review article: appropriate use of proton pump inhibitors with traditional nonsteroidal anti-inflammatory drugs and COX-2 selective inhibitors. Aliment Pharmacol Ther 2004;19(Suppl 1):60-5
   PubMed Web of Science ®Google Scholar
• Ofman JJ, Badamgarav E, Henning JM, et al. Utilization of nonsteroidal anti-inflammatory drugs and antisecretory agents: a managed care claims analysis. Am J Med 2004;116:835-42
   PubMed Web of Science ®Google Scholar
• Singh G, Ramey DR, Morfeld D, et al. Gastrointestinal tract complications of nonsteroidal anti-inflammatory drug treatment in rheumatoid arthritis. A prospective observational cohort study. Arch Intern Med 1996;156:1530-6
   PubMed Web of Science ®Google Scholar
• Targownik LE, Lix LM, Metge CJ, et al. Use of proton pump inhibitors and risk of osteoporosis-related fractures. CMAJ 2008;179:319-26
   PubMed Web of Science ®Google Scholar
• Yang YX, Lewis JD, Epstein S, et al. Long-term proton pump inhibitor therapy and risk of hip fracture. JAMA 2006;296:2947-53
   PubMed Web of Science ®Google Scholar
• Wright MJ, Proctor DD, Insogna KL, et al. Proton pump-inhibiting drugs, calcium homeostasis, and bone health. Nutr Rev 2008;66:103-8
   PubMed Web of Science ®Google Scholar
• Nardino RJ, Vender RJ, Herbert PN. Overuse of acid-suppressive therapy in hospitalized patients. Am J Gastroenterol 2000;95:3118-22
   PubMed Web of Science ®Google Scholar
• Naunton M, Peterson GM, Bleasel MD. Overuse of proton pump inhibitors. J Clin Pharm Ther 2000;25:333-40
   PubMed Web of Science ®Google Scholar
• Pham CQ, Sadowski-Hayes LM, Regal RE. Prevalent prescribing of proton pump inhibitors: Prudent or pernicious?. Pharm Ther 2006;31:159-67
   Google Scholar
• Dial S, Alrasadi K, Manoukian C, et al. Risk of Clostridium difficile diarrhea among hospital inpatients prescribed proton pump inhibitors: cohort and case-control studies. CMAJ 2004;171:33-8
   PubMed Web of Science ®Google Scholar
• Carvajal A, Arias LH, Vega E, et al. Gastroprotection during the administration of non-steroidal anti-inflammatory drugs. A drug-utilization study. Eur J Clin Pharmacol 2004;60:439-44
   PubMed Web of Science ®Google Scholar
• Wright JM. The double-edged sword of COX-2 selective NSAIDs. CMAJ 2002;167:1131-7
   PubMed Web of Science ®Google Scholar
• Peskar BM. Role of leukotrience C4 in mucosal damage caused by necrotizing agents and indomethacin in the rat stomach. Gasteroenterology 1991;100:619-26
   PubMed Web of Science ®Google Scholar
• Vane JR. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nat New Biol 1971;231:232-35
   PubMedGoogle Scholar
• Biswas K, Bandyopadhyay U, Chattopadhyay I, et al. A novel antioxidant and antiapoptotic role of omeprazole to block gastric ulcer through scavenging of hydroxyl radical. J Biol Chem 2003;278:10993-1001
   PubMed Web of Science ®Google Scholar
• Lapenna D, De Gioia S, Mezzetti A, et al. H2-receptor antagonists are scavengers of oxygen radicals. Eur J Clin Invest 1994;24:476-81
   PubMed Web of Science ®Google Scholar